Singapore markets open in 7 hours 56 minutes

Phathom Pharmaceuticals, Inc. (PHAT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.79+0.18 (+1.87%)
As of 12:42PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 354.38M
Enterprise value 308.90M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)9.32
Enterprise value/revenue N/A
Enterprise value/EBITDA -2.19

Trading information

Stock price history

Beta (5Y monthly) 0.98
52-week change 3-72.53%
S&P500 52-week change 3-12.09%
52-week high 337.17
52-week low 36.09
50-day moving average 38.99
200-day moving average 317.44

Share statistics

Avg vol (3-month) 3286.76k
Avg vol (10-day) 3279k
Shares outstanding 539.07M
Implied shares outstanding 6N/A
Float 818.76M
% held by insiders 124.48%
% held by institutions 167.15%
Shares short (14 Jun 2022) 43.24M
Short ratio (14 Jun 2022) 411.09
Short % of float (14 Jun 2022) 413.31%
Short % of shares outstanding (14 Jun 2022) 48.28%
Shares short (prior month 12 May 2022) 43.1M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)30 Mar 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-44.07%
Return on equity (ttm)-147.95%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -138.88M
Net income avi to common (ttm)-149.7M
Diluted EPS (ttm)-4.00
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)138.09M
Total cash per share (mrq)3.62
Total debt (mrq)92.61M
Total debt/equity (mrq)243.49
Current ratio (mrq)12.79
Book value per share (mrq)1.00

Cash flow statement

Operating cash flow (ttm)-143.95M
Levered free cash flow (ttm)-90M